Works about EMICIZUMAB

Results: 177

Concizumab, a Non-Replacement Therapy for Persons with Hemophilia with Inhibitors.

Published in:

Journal of Clinical Medicine, 2025, v. 14, n. 9, p. 2961, doi. 10.3390/jcm14092961

By:

Castaman, Giancarlo;
Jimenez-Yuste, Victor;
Mahlangu, Johnny

Publication type:

Article

Acquired Hemophilia—A Case Series and Review.

Published in:

Journal of Clinical Medicine, 2025, v. 14, n. 5, p. 1597, doi. 10.3390/jcm14051597

By:

Waldman Radinsky, Liat;
Sivan, Maayan;
Lubetsky, Aharon;
Misgav, Mudi;
Lalezari, Shadan;
Cohen, Omri;
Barhod, Tlalit;
Kenet, Gili;
Efros, Orly

Publication type:

Article

Dental Considerations in Children with Inherited Bleeding Disorders and Inhibitors: A Systematic Review.

Published in:

Journal of Clinical Medicine, 2024, v. 13, n. 24, p. 7743, doi. 10.3390/jcm13247743

By:

Vujkov, Sanja;
Bajkin, Branislav;
Blagojević, Duška;
Nešković, Isidora;
Komšić, Jelena;
Tadić, Ana;
Petrović, Bojan

Publication type:

Article

Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center.

Published in:

Journal of Clinical Medicine, 2024, v. 13, n. 9, p. 2646, doi. 10.3390/jcm13092646

By:

Carulli, Christian;
Daniele, Giovanna;
Linari, Silvia;
Pieri, Lisa;
Littera, Mariastefania;
Mazzetti, Matteo;
Tamburini, Carlo;
Prisco, Domenico;
Castaman, Giancarlo

Publication type:

Article

The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 19, p. 6320, doi. 10.3390/jcm12196320

By:

Matsumoto, Takeshi;
Wada, Hideo;
Shiraki, Katsuya;
Suzuki, Kei;
Yamashita, Yoshiki;
Tawara, Isao;
Shimpo, Hideto;
Shimaoka, Motomu

Publication type:

Article

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 6, p. 2317, doi. 10.3390/jcm12062317

By:

Castaman, Giancarlo;
Linari, Silvia;
Pieri, Lisa;
Carulli, Christian;
Prosperi, Paolo;
Tonelli, Paolo;
Demartis, Francesco;
Fjerza, Rajmonda;
Attanasio, Monica;
Coppo, Mirella;
Salvianti, Francesca

Publication type:

Article

A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 20, p. 6142, doi. 10.3390/jcm11206142

By:

Wada, Hideo;
Shiraki, Katsuya;
Matsumoto, Takeshi;
Suzuki, Kei;
Yamashita, Yoshiki;
Tawara, Isao;
Shimpo, Hideto;
Shimaoka, Motomu

Publication type:

Article

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab.

Published in:

Journal of Clinical Medicine, 2021, v. 10, n. 19, p. 4303, doi. 10.3390/jcm10194303

By:

Levy-Mendelovich, Sarina;
Brutman-Barazani, Tami;
Budnik, Ivan;
Avishai, Einat;
Barg, Assaf A.;
Levy, Tamara;
Misgav, Mudi;
Livnat, Tami;
Kenet, Gili

Publication type:

Article

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 1, p. 30, doi. 10.1002/cpdd.805

By:

Li, Haiyan;
Zhang, Weijiang;
Petry, Claire;
Li, Lindong;
Fernandez, Elena;
Kiialainen, Anna;
Feng, Sheng;
Hsu, Wanling;
Li, Li;
Wei, Yudong;
Schmitt, Christophe

Publication type:

Article

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2019, v. 8, n. 6, p. 702, doi. 10.1002/cpdd.617

By:

Kotani, Naoki;
Yoneyama, Koichiro;
Kawakami, Nobuhiko;
Shimuta, Tohru;
Fukase, Hiroyuki;
Kawanishi, Takehiko

Publication type:

Article

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience.

Published in:

Hematology Reports, 2023, v. 15, n. 4, p. 597, doi. 10.3390/hematolrep15040062

By:

Rener, Karla;
Doma, Saša Anžej;
Fink, Martina;
Podgornik, Helena;
Zupan, Irena Preložnik

Publication type:

Article

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab.

Published in:

2022

By:

Fumiya Inoue;
Kazuki Terada;
Kazuki Furudate;
Yasushi Noguchi;
Shunji Igarashi

Publication type:

Case Study

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence.

Published in:

Journal of Blood Medicine, 2021, v. 12, p. 1031, doi. 10.2147/JBM.S260923

By:

Dargaud, Yesim;
Janbain, Maissa

Publication type:

Article

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.

Published in:

Journal of Blood Medicine, 2021, v. 12, p. 115, doi. 10.2147/JBM.S288283

By:

Klamroth, Robert;
Wojciechowski, Piotr;
Aballéa, Samuel;
Diamand, Françoise;
Hakimi, Zalmai;
Nazir, Jameel;
Abad-Franch, Lydia;
Lethagen, Stefan;
Santagostino, Elena;
Tarantino, Michael D

Publication type:

Article

EMICIZUMAB THERAPY IN A HAEMOPHILIA PATIENT WITH PREVIOUS PULMONARY EMBOLISM.

Published in:

2020

By:

Holzmann, Jonathan;
Coulsen, Hayley;
Poulsen, Wendy;
McCosker, Joanna;
Harlen, Moana;
Brown, Simon

Publication type:

Letter

Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.

Published in:

PLoS ONE, 2022, v. 17, n. 7, p. 1, doi. 10.1371/journal.pone.0271330

By:

Hamedani, Nasim Shahidi;
Oldenburg, Johannes;
Pötzsch, Bernd;
Müller, Jens

Publication type:

Article

Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.

Published in:

Clinical & Experimental Medicine, 2024, v. 25, n. 1, p. 1, doi. 10.1007/s10238-024-01528-4

By:

Raventós, Aida;
Arias-Salgado, Elena G.;
Pérez, Alba;
Alvarez-Román, María Teresa;
Butta, Nora V.;
Monzon Manzano, Elena;
Acuña, Paula;
Jiménez-Yuste, Víctor;
Costa, Montserrat;
Bravo, María Isabel

Publication type:

Article

Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review.

Published in:

Clinical & Applied Thrombosis/Hemostasis, 2024, v. 30, p. 1, doi. 10.1177/10760296241298661

By:

Ikbel, Ghachem;
Hela, Baccouche;
Yassine, Kaabar Mohamed;
Hamida, Khemiri;
Kamel, Ben Salem

Publication type:

Article

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A.

Published in:

Clinical & Applied Thrombosis/Hemostasis, 2022, v. 28, p. 1, doi. 10.1177/10760296221143382

By:

Iarossi, Michael;
Lambert, Catherine;
Hermans, Cedric

Publication type:

Article

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.

Published in:

Clinical & Applied Thrombosis/Hemostasis, 2022, v. 28, p. 1, doi. 10.1177/10760296221082992

By:

Hatayama, Yuki;
Motokura, Toru;
Hosoda, Yuzuru;
Suzuki, Sayaka;
Namba, Hiroya;
Kato, Konami;
Kojima, Nao;
Horie, Takuya;
Iwamoto, Takuya;
Yamashita, Noriko;
Ichikawa, Hitomi;
Fukuda, Tetsuya

Publication type:

Article

Emicizumab: A Review in Haemophilia A.

Published in:

Drugs, 2019, v. 79, n. 15, p. 1697, doi. 10.1007/s40265-019-01200-2

By:

Blair, Hannah A.

Publication type:

Article

Laboratory response to paradigm change in hemophilia treatment: How to monitor patients simultaneously treated with emicizumab and Factor VIII concentrate?

Published in:

Clinical Chemistry & Laboratory Medicine, 2023, v. 61, n. 12, p. e248, doi. 10.1515/cclm-2023-0443

By:

Shafaati Lambert, Marjan;
Bruzelius, Maria;
Mahmoud Hourani Soutari, Nida;
Ranta, Susanna;
Antovic, Jovan P.

Publication type:

Article

Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.

Published in:

Clinical Chemistry & Laboratory Medicine, 2021, v. 59, n. 1, p. 365, doi. 10.1515/cclm-2020-0696

By:

Tripodi, Armando;
Chantarangkul, Veena;
Novembrino, Cristina;
Scalambrino, Erica;
Boscolo-Anzoletti, Massimo;
Clerici, Marigrazia;
Rossi, Federica;
Peyvandi, Flora

Publication type:

Article

Evaluation of the Care Pathway in the Context of the Dispensing of Emicizumab (Hemlibra) in Community Pharmacies in France: Protocol for a Cross-sectional Study Based on the Kirkpatrick Model.

Published in:

JMIR Research Protocols, 2023, v. 12, n. 1, p. 950, doi. 10.2196/43091

By:

Fraticelli, Laurie;
Freyssenge, Julie;
Promé-Combel, Emilie;
Agnellet, Eléonore;
Dargaud, Yesim;
Chamouard, Valérie

Publication type:

Article

Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A.

Published in:

Drugs - Real World Outcomes, 2024, v. 11, n. 3, p. 541, doi. 10.1007/s40801-024-00420-7

By:

Bingo, Masato;
Fukutake, Katsuyuki;
Togo, Kanae;
Xu, Linghua;
Alvir, José Maria Jimenez;
Winburn, Ian;
Karumori, Toshiyuki

Publication type:

Article

Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile.

Published in:

American Journal of Case Reports, 2021, v. 22, p. 1, doi. 10.12659/AJCR.929598

By:

Abarca-Villaseca, Viviana;
Soto-Arellano, Verónica

Publication type:

Article

Mimetics of active factor VIII (FVIIIa) and their impact on laboratory tests of haemostasis.

Published in:

Journal of Transfusion Medicine, 2023, v. 16, n. 4, p. 260, doi. 10.5603/jtm.99303

By:

Odnoczko, Edyta

Publication type:

Article

Verification and Implementation of a Bovine Chromogenic Factor VIII Assay for Hemophilia A Patients on Emicizumab Therapy.

Published in:

Clinical Laboratory, 2024, v. 70, n. 12, p. 2370, doi. 10.7754/Clin.Lab.2024.240521

By:

Masia, Tlangelani V.;
Louw, Susan

Publication type:

Article

Health-related quality of life in children with severe hemophilia A on emicizumab prophylaxis.

Published in:

Egyptian Journal of Haematology, 2024, v. 49, n. 2, p. 192, doi. 10.4103/ejh.ejh_3_24

By:

Hassan, Ahmed S.;
Sherief, Laila M.;
Hamdy, Mona;
Abbas, Ahmed M.;
Elagamy, Osama

Publication type:

Article

Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis.

Published in:

British Journal of Clinical Pharmacology, 2023, v. 89, n. 2, p. 908, doi. 10.1111/bcp.15598

By:

Gelbenegger, Georg;
Traby, Ludwig;
Rahimi, Nina;
Knöbl, Paul

Publication type:

Article

A Unique Comparison of Tooth Extraction Before and After Emicizumab Prophylaxis in a Patient With Haemophilia A and Inhibitors.

Published in:

2025

By:

Zaizen, Miki;
Yagyuu, Takahiro;
Yata, Sachiko;
Nakamura, Hiroshi;
Imada, Mitsuhiko;
Yamakawa, Nobuhiro;
Nammour, Samir

Publication type:

Case Study

A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.

Published in:

Current Medical Research & Opinion, 2022, v. 38, n. 10, p. 1685, doi. 10.1080/03007995.2022.2105072

By:

Batt, Katharine;
Schultz, Bob G.;
Caicedo, Jorge;
Hollenbeak, Christopher S.;
Agrawal, Neha;
Chatterjee, Sagnik;
Bullano, Michael

Publication type:

Article

Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.

Published in:

International Journal of Clinical Pharmacy, 2023, v. 45, n. 3, p. 622, doi. 10.1007/s11096-022-01514-4

By:

Wei, Lianhui;
Tian, Ye;
Chen, Xiao;
Guo, Xiaojing;
Chen, Chenxin;
Zheng, Yi;
Xu, Jinfang;
Ye, Xiaofei

Publication type:

Article

Utilization of Emicizumab in Acquired Factor VIII Deficiency.

Published in:

American Journal of Case Reports, 2020, v. 21, p. 1, doi. 10.12659/AJCR.922326

By:

Hess, Kevin J.;
Patel, Preysi;
Joshi, Amogh M.;
Kotkiewicz, Adam

Publication type:

Article

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.

Published in:

2020

By:

Linari, Silvia;
Castaman, Giancarlo

Publication type:

journal article

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.

Published in:

Clinical Pharmacokinetics, 2021, v. 60, n. 11, p. 1395, doi. 10.1007/s40262-021-01042-w

By:

Donners, Anouk A. M. T.;
Rademaker, Carin M. A.;
Bevers, Lisanne A. H.;
Huitema, Alwin D. R.;
Schutgens, Roger E. G.;
Egberts, Toine C. G.;
Fischer, Kathelijn

Publication type:

Article

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.

Published in:

Clinical Pharmacokinetics, 2021, v. 60, n. 7, p. 931, doi. 10.1007/s40262-021-01006-0

By:

Jonsson, Fredrik;
Schmitt, Christophe;
Petry, Claire;
Mercier, Francois;
Frey, Nicolas;
Retout, Sylvie

Publication type:

Article

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A.

Published in:

Clinical Pharmacokinetics, 2020, v. 59, n. 12, p. 1611, doi. 10.1007/s40262-020-00904-z

By:

Retout, Sylvie;
Schmitt, Christophe;
Petry, Claire;
Mercier, François;
Frey, Nicolas

Publication type:

Article

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report.

Published in:

2023

By:

Albattat, Sami;
Alabdultaif, Abbas;
Albattat, Fatimah;
Albattat, Batla

Publication type:

Case Study

Dental extractions on a patient with severe haemophilia A and inhibitors taking emicizumab prophylaxis. A case report and review.

Published in:

Oral Surgery (1752-2471), 2022, v. 15, n. 4, p. 592, doi. 10.1111/ors.12689

By:

Hamid, Aruche‐A‐Noor;
Smithson, Nigel

Publication type:

Article

Prophylaxie de l'hémophilie en pédiatrie.

Published in:

Hematologie, 2024, v. 30, n. 6, p. 351, doi. 10.1684/hma.2024.1871

By:

Harroche, Annie;
Meunier, Sandrine

Publication type:

Article

What proceduralists need to know about emicizumab for patients with hemophilia A.

Published in:

Baylor University Medical Center Proceedings, 2021, v. 34, n. 2, p. 334, doi. 10.1080/08998280.2020.1851628

By:

Pivalizza, Evan G.;
Escobar, Miguel

Publication type:

Article

Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.

Published in:

Annals of Hematology, 2024, v. 103, n. 8, p. 2647, doi. 10.1007/s00277-023-05287-2

By:

Shima, Midori

Publication type:

Article

Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry.

Published in:

Haemophilia, 2025, v. 31, n. 3, p. 433, doi. 10.1111/hae.70039

By:

Fischer, Kathelijn;
Lassila, Riitta;
Peyvandi, Flora;
Gatt, Alex;
Gouw, Samantha C.;
Hollingsworth, Rob;
Lambert, Thierry;
Kaczmarek, Radoslaw;
Carbonero, Diana;
Makris, Michael

Publication type:

Article

In vitro combined haemostatic efficacy of emicizumab and extended half‐life factor VIII compounds.

Published in:

Haemophilia, 2025, v. 31, n. 2, p. 224, doi. 10.1111/hae.15131

By:

Josset, Laurie;
Rezigue, Hamdi;
Nougier, Christophe;
Leuci, Alexandre;
Désage, Stéphanie;
Lienhart, Anne;
Dargaud, Yesim

Publication type:

Article

The impact of emicizumab on the clinical validation of new therapies for haemophilia A.

Published in:

Haemophilia, 2025, v. 31, n. 2, p. 331, doi. 10.1111/hae.15112

By:

Hermans, Cedric;
Lambert, Catherine;
Lobet, Sébastien;
Krumb, Evelien;
Van Damme, An

Publication type:

Article

Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype.

Published in:

Haemophilia, 2025, v. 31, n. 1, p. 122, doi. 10.1111/hae.15146

By:

Kessakorn, Nuchanun;
Gosriwatana, Itsaraet;
Sasipong, Nuttarak;
Srichumpuang, Chonlatis;
Moonla, Chatphatai;
Sosothikul, Darintr

Publication type:

Article

Pain‐Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies.

Published in:

Haemophilia, 2025, v. 31, n. 1, p. 87, doi. 10.1111/hae.15134

By:

Hermans, Cedric;
Skinner, Mark W.;
Gentile, Brittany;
Lim, Elise;
Minhas, Miranda;
Moreno, Katya;
Tzeng, Eunice;
Buckner, Tyler W.

Publication type:

Article

Assessment of haemophilic joints in a low‐resourced area using clinical tools: The effect of different types of prophylaxis.

Published in:

Haemophilia, 2024, v. 30, n. 6, p. 1414, doi. 10.1111/hae.15115

By:

Youssry, Ilham;
El‐Taweel, Rania;
Seif, Hadeel;
Sami, Rania;
Okasha, Karim;
Taha, Ebtehal;
Haffar, Assad;
Elhady, Marwa Abd

Publication type:

Article

Evaluating the benefits of emicizumab prophylaxis for haemophilia A with inhibitors: A cost‐effectiveness and budget impact analysis in Thailand's upper‐middle income setting.

Published in:

Haemophilia, 2024, v. 30, n. 6, p. 1288, doi. 10.1111/hae.15105

By:

Kengkla, Kirati;
Wilairat, Preyanate;
Natesirinilkul, Rungrote;
Sosothikul, Darintr;
Phisalprapa, Pochamana;
Saokaew, Surasak

Publication type:

Article